BRCA1 and breast carcinoma: In addition, BRCA1 promoter hypermethylation correlates with a higher risk of recurrence, reduced survival rates of breast cancer [16,17], and it can affect the response to certain chemotherapy agents and targeted therapies, such as platinum-derived therapy and PARP inhibitors [18,19].